Insights
How Leap reduces the total cost of multiple sclerosis care
For patients requiring long-term MS infusions like Ocrevus or Tysabri, traditional hospital-based treatment comes at a significant financial and logistical cost. Leap provides an alternative: cost-effective, patient-friendly infusion therapy that eliminates unnecessary expenses and administrative barriers.
Key areas where Leap saves employers money
Leap Health's model addresses the biggest cost drivers in MS treatment by:
- Eliminating unnecessary drug markups: On average, Leap saves $51,000 annually per patient.Leap Health’s pass-through pricing ensures employers pay the actual cost of MS drugs, with no additional markups.
- Reducing site-of-service costs: Leap shifts patients away from high-cost hospital outpatient infusions, which can inflate treatment costs by up to 500%.With home infusion, patients avoid facility fees and excessive administrative costs.
- Improving adherence and reducing long-term disability: Missed or delayed infusions lead to worsening symptoms, hospitalizations and long-term disability claims.Leap Health’s proactive care coordination ensures MS patients stay on schedule, reducing complications and improving health outcomes.
- Enhancing workforce productivity: The average MS patient spends an entire day off work for an infusion due to travel, long wait times and post-treatment recovery.Leap Health cuts infusion time to just two hours at home, allowing patients to return to work and daily activities sooner.
March is national MS education and awareness month
March is a time to raise awareness about MS and advocate for better, more affordable care. For employers, this means recognizing the significant financial and workforce burden that MS places on their organizations and taking action to reduce these costs without sacrificing care quality.
Leap is committed to making MS treatment more accessible, cost-effective, and patient-friendly. By eliminating inflated infusion costs and reducing workplace disruptions, Leap helps employers provide better care while saving millions annually.
More insights
The $400K signal: What six months of Leap data says about the specialty drug trend
Luka is a child managing pediatric Crohn's disease. His care team prescribed Remicade, an infusion t...
5 steps to implement a specialty infusion therapy program employees will actually use
Choosing the right vendor helps you understand the savings that are possible. But the right implemen...
What cancer patients can expect from oncology infusion and injection therapies
When chemotherapy ends for an oncology patient, the nausea and hair loss may ease. But a new phase o...
Bringing relief for Luka: From hospital stays to at-home infusion care
Luka is a child managing pediatric Crohn's disease. His care team prescribed Remicade, an infusion t...
What is home infusion therapy? A guide for patients and their families.
More patients and employers are choosing home infusion as a safe, effective alternative to hospital-...
You don't know what you're buying today with specialty infusion therapy. That’s how the model was built.
A member on Remicade needs an infusion every six to eight weeks. Her employer sees one number on the...
Rising healthcare costs for employers projected to reach historic levels in 2027.
Rising healthcare costs are set to hit their sharpest increase in decades in 2027. See what's actual...
Site of care alone doesn’t guarantee savings. Dependable pricing does.
For two years, Matt made a four-hour round trip from his home in Mississippi to an infusion clinic i...
Why specialty infusion therapy must be top of mind in your 2027 benefits planning
One of your employees has multiple sclerosis and requires ongoing infusion therapy. Meanwhile, your ...
From hospital to home: The specialty infusion experience your members are missing
A woman with rheumatoid arthritis drives 90 minutes to a hospital outpatient department for her Infl...